Humalog

Humalog is a rapid‑acting insulin analog whose active ingredient is insulin lispro, supplied as an injection solution for subcutaneous or intravenous use. It is marketed in the European Union and is currently available only by prescription. The formulation provides a quick onset of action to help control post‑prandial blood glucose in people with diabetes. Humalog does not contain a fixed numerical strength in this description.

Humalog is indicated for the management of blood glucose in adults and children with diabetes.

- Type 1 diabetes mellitus, as part of basal‑bolus insulin therapy. - Type 2 diabetes mellitus, when rapid glucose control is needed. - Post‑prandial hyperglycemia, to reduce glucose spikes after meals. - Hospitalized patients requiring intravenous insulin infusion for tight glycemic control. - Use in insulin pump therapy where rapid‑acting insulin is required.

Adverse reactions to Humalog may vary in frequency and severity.

Common: - Low blood sugar (hypoglycemia), especially if meals are missed or delayed. - Injection site reactions such as redness, swelling, or itching. - Lipodystrophy, including lipohypertrophy at repeated injection sites. - Weight gain associated with improved glycemic control.

Serious: - Severe hypoglycemia leading to loss of consciousness or seizures. - Allergic reactions ranging from urticaria to anaphylaxis. - Edema or heart failure exacerbation in susceptible patients. - Persistent hyperglycemia indicating possible insulin resistance.

When prescribing or using Humalog, several precautions should be considered to ensure safe and effective therapy.

- Assess renal and hepatic function, as impairment may alter insulin clearance. - Adjust dose during periods of illness, stress, or changes in physical activity. - Monitor blood glucose closely when initiating therapy or changing the injection site. - Use caution in pregnant or breastfeeding individuals; consult a healthcare professional. - Review patient history for hypoglycemia unawareness or prior severe episodes. - Consider cardiovascular status, as rapid‑acting insulin can affect fluid balance.

Humalog can interact with other medicines, affecting glucose control or increasing the risk of adverse events.

Avoid: - Concurrent use of other rapid‑acting insulins or high‑dose insulin secretagogues without dose adjustment. - Beta‑blockers that may mask hypoglycemia symptoms. - MAO‑A inhibitors that can potentiate insulin’s glucose‑lowering effect.

Use with caution: - Oral antidiabetic agents such as sulfonylureas, meglitinides, or SGLT2 inhibitors; monitor for hypoglycemia. - Corticosteroids, which may raise blood glucose and require dose changes. - Alcohol consumption, which can cause delayed hypoglycemia.